Xenofon Baraliakos
About
Xenofon Baraliakos is a scholar working on Rheumatology, Immunology and Hematology.
According to data from OpenAlex, Xenofon Baraliakos has authored 585 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 520 papers in Rheumatology, 257 papers in Immunology and 138 papers in Hematology. Recurrent topics in Xenofon Baraliakos's work include Spondyloarthritis Studies and Treatments (467 papers), Rheumatoid Arthritis Research and Therapies (297 papers) and Psoriasis: Treatment and Pathogenesis (223 papers). Xenofon Baraliakos is often cited by papers focused on Spondyloarthritis Studies and Treatments (467 papers), Rheumatoid Arthritis Research and Therapies (297 papers) and Psoriasis: Treatment and Pathogenesis (223 papers). Xenofon Baraliakos collaborates with scholars based in Germany, United States and Netherlands. Xenofon Baraliakos's co-authors include Jürgen Braun, Joachim Sieper, Désirée van der Heijde, Martín Rudwaleit, Joachim Listing, Kay‐Geert Hermann, J. Brandt, Hildrun Haibel, Robert Landewé and Maxime Dougados and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.
In The Last Decade
Xenofon Baraliakos
542 papers receiving 15.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Xenofon Baraliakos Germany | 62 | 14.0k | 7.5k | 4.6k | 3.0k | 1.2k | 585 | 15.8k | ||
| Martín Rudwaleit Germany | 71 | 17.1k 1.2× | 9.0k 1.2× | 5.2k 1.1× | 3.0k 1.0× | 1.4k 1.2× | 310 | 18.8k | ||
| Joachim Listing Germany | 65 | 12.5k 0.9× | 6.2k 0.8× | 4.7k 1.0× | 1.5k 0.5× | 1.0k 0.9× | 179 | 14.8k | ||
| Walter P. Maksymowych Canada | 70 | 14.4k 1.0× | 6.9k 0.9× | 4.5k 1.0× | 4.2k 1.4× | 1.8k 1.6× | 520 | 18.0k | ||
| Filip Van den Bosch Belgium | 53 | 8.8k 0.6× | 5.4k 0.7× | 3.5k 0.8× | 835 0.3× | 951 0.8× | 303 | 11.0k | ||
| Denis Poddubnyy Germany | 46 | 7.0k 0.5× | 4.2k 0.6× | 2.2k 0.5× | 1.3k 0.4× | 583 0.5× | 357 | 7.8k | ||
| Atul Deodhar United States | 50 | 6.8k 0.5× | 5.0k 0.7× | 2.8k 0.6× | 568 0.2× | 604 0.5× | 307 | 9.1k | ||
| Herman Mielants Belgium | 49 | 8.6k 0.6× | 4.9k 0.7× | 3.3k 0.7× | 687 0.2× | 910 0.8× | 214 | 10.9k | ||
| Andrei Călin United Kingdom | 46 | 8.2k 0.6× | 3.9k 0.5× | 2.4k 0.5× | 767 0.3× | 743 0.6× | 150 | 9.5k | ||
| A. Cats Netherlands | 36 | 8.7k 0.6× | 3.7k 0.5× | 2.4k 0.5× | 1.1k 0.4× | 995 0.9× | 124 | 10.6k | ||
| Annette H M van der Helm–van Mil Netherlands | 56 | 9.6k 0.7× | 2.3k 0.3× | 2.1k 0.5× | 362 0.1× | 1.2k 1.0× | 350 | 12.3k |
Countries citing papers authored by Xenofon Baraliakos
Since
Specialization
Citations
This map shows the geographic impact of Xenofon Baraliakos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xenofon Baraliakos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xenofon Baraliakos more than expected).
Fields of papers citing papers by Xenofon Baraliakos
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Xenofon Baraliakos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xenofon Baraliakos. The network helps show where Xenofon Baraliakos may publish in the future.
Co-authorship network of co-authors of Xenofon Baraliakos
This figure shows the co-authorship network connecting the top 25 collaborators of Xenofon Baraliakos. A scholar is included among the top collaborators of Xenofon Baraliakos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xenofon Baraliakos. Xenofon Baraliakos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Deodhar, Atul, Victoria Navarro‐Compán, Denis Poddubnyy, et al.. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 11(1). e005081–e005081.
2.
Triantafyllias, Konstantinos, et al.. (2025). Inflammation assessment in psoriatic arthritis via optical spectral transmission: correlations with clinical markers and musculoskeletal ultrasound. Lara D. Veeken. 65(1).
3.
Reich, Andreas, Anja Weiß, J. Detert, et al.. (2025). Effect of depressive symptoms on treatment response in patients with axSpA: data from the RABBIT-SpA register. RMD Open. 11(2). e005422–e005422.
4.
Bosch, Filip Van den, Atul Deodhar, Denis Poddubnyy, et al.. (2025). Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Research & Therapy. 27(1). 23–23.
5.
Heijde, Désirée van der, Victoria Navarro‐Compán, R. Landewé, et al.. (2025). 1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis. Annals of the Rheumatic Diseases. 84(3). 382–387.
6.
Baraliakos, Xenofon, Mikhail Protopopov, Valeria Ríos Rodríguez, et al.. (2025). Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring. Annals of the Rheumatic Diseases. 84(8). 1335–1341.
7.
Gossec, Laure, Xenofon Baraliakos, Daniel Aletaha, et al.. (2024). Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS. Lara D. Veeken. 64(5). 2565–2574.
8.
Baraliakos, Xenofon, et al.. (2024). Enthesopathies – Mechanical, inflammatory or both?. Best Practice & Research Clinical Rheumatology. 38(1). 101966–101966.
9.
Pfeil, Alexander, Martin Fleck, Martin Aringer, et al.. (2024). Kriterien für die Weiterbildungsbefugnis zur Facharztkompetenz Innere Medizin und Rheumatologie – ein Positionspapier der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie. Zeitschrift für Rheumatologie. 84(1). 59–67.
10.
Kiltz, Uta, et al.. (2024). Patientenorientierte Optimierung der Versorgungsqualität in der ambulanten spezialfachärztlichen Versorgung (ASV) in einem tertiären rheumatologischen Zentrum. Zeitschrift für Rheumatologie. 84(1). 19–29.
11.
Hooge, Manouk de, Alexandre Sepriano, Xenofon Baraliakos, et al.. (2024). Inflammation in the posterior elements, in particular the facet joint and facet joint ankylosis over 2-year follow-up in radiographic axial spondyloarthritis. RMD Open. 10(2). e004199–e004199.
12.
Baraliakos, Xenofon, et al.. (2023). Treatment overview of axial spondyloarthritis in 2023. Best Practice & Research Clinical Rheumatology. 37(3). 101858–101858.
13.
Ziadé, Nelly, Bassel Elzorkany, Lina El Kibbi, et al.. (2023). What is the best referral strategy for axial spondyloarthritis? A prospective multicenter study in patients with suspicious chronic low back pain. Joint Bone Spine. 90(5). 105579–105579.
14.
Feist, Eugen, Xenofon Baraliakos, Frank Behrens, et al.. (2022). Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes. Rheumatology and Therapy. 9(2). 621–635.
15.
Santos-Moreno, P., Xenofon Baraliakos, & Rodrigo García Salinas. (2021). Engagement process for patients with spondyloarthritis: PANLAR early SpA clinics project — centers of excellence. Clinical Rheumatology. 40(11). 4759–4766.
16.
Deodhar, Atul, Huji Xu, Xenofon Baraliakos, et al.. (2021). Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 80(8). 1004–1013.
17.
Maksymowych, Walter P., Mikkel Østergaard, Robert Landewé, et al.. (2021). Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Lara D. Veeken. 61(6). 2388–2397.
18.
Choy, Ernest, Xenofon Baraliakos, Frank Behrens, et al.. (2019). The need for comparative data in spondyloarthritis. Arthritis Research & Therapy. 21(1). 32–32.
19.
Mandl, Péter, Lene Terslev, Xenofon Baraliakos, et al.. (2019). Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR. RMD Open. 5(2). e000950–e000950.
20.
Braun, Jürgen, Xenofon Baraliakos, Joachim Listing, et al.. (2007). Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents. Arthritis Care & Research. 57(4). 639–647.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Martín Rudwaleit Breakdown of academic impact, for papers by Joachim Listing Breakdown of academic impact, for papers by Walter P. Maksymowych Breakdown of academic impact, for papers by Filip Van den Bosch Breakdown of academic impact, for papers by Denis Poddubnyy Breakdown of academic impact, for papers by Atul Deodhar Breakdown of academic impact, for papers by Herman Mielants Breakdown of academic impact, for papers by Andrei Călin Breakdown of academic impact, for papers by A. Cats Breakdown of academic impact, for papers by Annette H M van der Helm–van Mil